F. lymphoproliferated diseases (lymphoma, myeloma)

Cellular factors of antitumor immunity in patients with chronic lympholeukemia

Natalya V. Issayeva, Galina A. Zaitseva, Tamara P. Zagoskina

Clinical and pathological characterization of the t(14;19)(q32;q13)-positive splenic marginal zone lymphoma

Hunan L. Julhakyan, Tatyana N. Obukhova, Irina B. Kaplanskaya, Rima S. Samoylova, Andrey I. Vorobiev

Cases of secondary acute myeloid leukemia and myelodysplastic syndrome in patients with multiple myeloma

Alexander S. Luchinin

Expression of tumor-associated genes in multiple myeloma patients during high-dose chemotherapy and auto-SCT

Tatiana V. Gaponova, Lidia S. Mendeleeva, Andrey V. Misurin, Elena Yu. Varlamova, Elena N. Parovichnikova,
Valeriy G. Savchenko

Prognostic value of apoptosis of tumor clone bone marrow cells in patients with multiple myeloma

Zhanna V. Chubukina, Ludmila N. Bubnova, Stanislav S. Bessmeltsev

Treatment results of children with Hodgkin’s disease (HD) according to protocols DAL-HD and GPOH-HD

Margarita B. Belogurova^1,2, Galina G. Radulesku^1,2, Tatyana D. Viktorovich^1,2, Emilia D. Chavpetsova², Ludmila I. Shats^1,2, Yulia V. Dinikina¹

Salvage therapy in relapsed Hodgkin's lymphoma patients

Elena S. Belyaeva, Olga V. Morozova, Andrey I. Slugin, Alexander V. Popa, Georgy L. Mentkevich

Supporting therapy of natural zeolites at patients with lymphoproliferative diseases

Anna S. Chernyshova, Lev E. Panin

Anemias in lymphomas: pathogenesis mechanisms

Anna S. Lyamkina, Tatiana I. Pospelova

Impact of positron emission tomography on primary staging and changing the therapeutic modality in lymphoma patients

Natalia B. Mikhaylova¹, Marina S. Tlostanova², Yulia N. Vinogradova², Ekaterina I. Ivanova², Anna V. Kritskaya², Sergey E. Korolev¹, Anna A. Rats¹, Alexander A. Pugachev¹, Nikolay V. Ilyin², Boris V. Afanasyev¹, Leonid A. Tyutin²

High-dose melphalan versus melphalan plus dexamethasone in patients with AL amyloidosis

Anna G. Smirnova¹, Alexey V. Smirnov², Axel R. Zander³, Boris V. Afanasyev¹

Allogeneic stem cell transplantation in multiple myeloma: single centre experience of 112 patients

Liisa Volin, Heli Uotinen, Eeva Juvonen, Anne Nihtinen, Tapani Ruutu

The role of p53 polymorphisms in non–Hodgkin’s lymphomas’ susceptibility and prognosis

Elena N. Voropaeva, Tatiana I. Pospelova, Mikhail I. Voevoda, Olga V. Beresina

Effects of targeted therapy of multiple myeloma according to the City Hematological Center of Novosibirsk

Natalia V. Skvortsova, Tatiana I. Pospelova, Sofia J. Kovalchuk

Association between HLA class I antigens and survival length in patients with multiple myeloma

Elena A. Senkina, Galina A. Zaitseva, Tamara P. Zagoskina, Konstantin A. Martynov

Genetic polymorphisms of CYP1A1, GSTM1, GSTT1, and GSTP1 genes in В-cellular chronic lymphocytic leukemia (B-CLL)

Vanik A. Ovsepyan, Vitaliy A. Rosin

Unusual B-cell lymphoproliferative disorders and the new WHO classification

Margarita Palutke

Bone marrow angiogenesis is a prognostic value in patients with multiple myeloma undergoing high-dose therapy and autologous stem cell transplantation

Olga S. Pokrovskaya, Lidia S. Mendeleeva, Irina B. Kaplanskaya, Elena Yu. Varlamova, Elena N. Parovichnikova, Sergey M. Kulikov, Valeriy G. Savchenko

Virus participation in renal damage in AL patients: histopathological study

Ekaterina G. Vorozheikina¹, Vladimir V. Varshavski², Ekaterina P. Golitsina², Evgenia N. Glasko¹, Irina B. Kaplanskaya¹, Ljudmila S. Birjukova¹, Elena N. Parovichnikova¹, Valeriy G. Savchenko¹

F. Lymphoproliferated diseases (Lymphoma, Myeloma)